Osilodrostat phosphate

磷酸奥唑司他

Report date: 2025/11/21 16:02:23
NMEFirst In Class

Base Information

Drug NameOsilodrostat phosphate
Drug Alias Nameosilodrostat奥唑司他奥西卓司他磷酸奥西卓司他Isturisa +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSteroid 11-beta-hydroxylase inhibitors
TargetsSteroid 11-beta-hydroxylase
Therapy Area/IndicationsACTH-independent macronodular adrenal hyperplasiaHyperaldosteronismCushing Syndrome +[9] 
Global Approved IndicationsCushing Syndrome
Approved Indications in ChinaCushing Syndrome
Original Approved Country/TerritoryEU
Original Approved Date2020/01/09
Country/TerritoryBelgiumBulgariaCanada +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesRecordati Rare Diseases IncNovartis Pharma Stein AgRecordati Spa +[4] 
Inactive CompaniesNovartis Pharma AgRecordati (Beijing) Pharmaceutical Co LtdBeijing Novartis Pharma Co Ltd
Active IndicationsCushing Syndrome
Inactive IndicationsACTH-independent macronodular adrenal hyperplasiaHyperaldosteronismEssential Hypertension +[8] 

Other Information

ATC CodeH02CA02
Related LinksWikipediaDrugBankKEGG